Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

upinitatug

A proprietary humanized monoclonal antibody against human sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi2b), with potential antineoplastic activity. Upon administration of upinitatug, the antibody targets and binds to NaPi2b expressed on tumor cells. Although the tumor cell killing effects of upinitatug are not established, this binding may induce an antibody-dependent cellular cytotoxicity (ADCC)-mediated immune response against NaPi2b-expressing tumor cells, and/or may inhibit NaPi2b-mediated sodium and phosphate ion cotransport activity and ion-dependent tumor cell signaling. NaPi2b, a tumor-associated antigen (TAA), is overexpressed on a variety of tumor cells. It plays a key role in the transport of inorganic phosphate (Pi) and the maintenance of phosphate homeostasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-NaPi2b MoAb XMT-1535
anti-NaPi2b monoclonal antibody XMT-1535
MoAb XMT-1535
upifitamab
Code name:XMT 1535
XMT-1535
XMT1535
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search